US · Healthcare · Biotechnology
EPS came in at -0.46 against a street estimate of -0.48 — a beat of 4.2%.
Analysts rate Edgewise Therapeutics Inc a buy (8 buy, 2 hold, 0 sell out of 10) with an average price target of $49.92.
| Fund | Stake |
|---|---|
| Orbimed Advisors, LLC | 14.42% |
| RA Capital Management, LLC | 9.69% |
| Paradigm Biocapital Advisors LP | 6.85% |
| Baker Bros Advisors LP | 6.11% |
| BlackRock Inc | 6.02% |
| HHG PLC | 5.50% |
| Novo A/S | 4.97% |
| Driehaus Capital Management LLC | 4.16% |
| Document | Date |
|---|---|
| Acquisition completed · Q3 2026 | 2026-07-13 |
| Shareholder vote results · Q2 2026 | 2026-06-05 |
| Material agreement · Q2 2026 | 2026-06-01 |
| Results announced · Q2 2026 | 2026-05-07 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Proxy statement · Q2 2026 | 2026-04-23 |
| Annual report FY2025 | 2026-02-26 |
| Quarterly report · Q3 2025 | 2025-11-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Edgewise Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.